Press release
Diabetic Kidney Disease Clinical Trials and Pipeline Analysis: EMA, PDMA, FDA Approvals, Medication, NDA, IND, Therapies, Treatment Market, Mechanism of Action, Route of Administration, and Companies by DelveInsight
Diabetic Kidney Disease Clinical Trials
The Diabetic Kidney Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Request for Sample Report @ https://www.delveinsight.com/sample-request/diabetic-kidney-disease-dkd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Some of the key takeaways from the Diabetic Kidney Disease Pipeline Report:
• Diabetic Kidney Disease Companies across the globe are diligently working toward developing novel Diabetic Kidney Disease treatment therapies with a considerable amount of success over the years.
• Diabetic Kidney Disease companies working in the treatment market are Orbsen Therapeutics, Dimerix Bioscience, Inversago Pharma, CSL Behring, Kyowa kirin, and others, are developing therapies for the Diabetic Kidney Disease treatment
• Emerging Diabetic Kidney Disease therapies in the different phases of clinical trials are- ORBCEL-M, DMX-200, INV-202, CSL346, Bardoxolone methyl, and others are expected to have a significant impact on the Diabetic Kidney Disease market in the coming years.
• On March 05, 2024, a multinational pharmaceutical company announced the results from the kidney outcomes trial FLOW. The double-blind trial compared injectable semaglutide 1.0 mg with placebo as an adjunct to standard of care for prevention of progression of kidney impairment and risk of kidney and cardiovascular mortality in people with type 2 diabetes and chronic kidney disease (CKD). In the trial, semaglutide 1.0 mg appeared to have a safe and well-tolerated profile in line with previous semaglutide 1.0 mg trials.
• In February 2023, The European Commission approved a label extension for Kerendia (finerenone) in the European Union (EU) that includes cardiovascular (CV) outcomes from the Phase III FIGARO-DKD research. The study found that Kerendia lowered the risk of cardiovascular events in a large sample of patients with CKD stages 1-4 and T2D. Kerendia is currently recommended for the treatment of chronic kidney disease (albuminuria) in individuals with type 2 diabetes.
• In July 2021, In people with chronic kidney disease linked with type 2 diabetes, the FDA approved Bayer Ag's Kerendia (finerenone) tablets to lower the risk of declining kidney function, kidney failure, non-fatal heart attacks, cardiovascular death, and hospitalization due to heart failure.
Diabetic Kidney Disease Overview
Diabetic Kidney Disease (DKD), also known as diabetic nephropathy, is a serious complication of diabetes characterized by progressive damage to the kidneys due to prolonged high blood sugar levels. It is a leading cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide. Diabetic Kidney Disease affects nearly 30-40% of individuals with diabetes and significantly increases the risk of cardiovascular disease and mortality.
The disease develops due to prolonged hyperglycemia and hypertension, which damage the glomeruli-the kidney's filtering units-leading to proteinuria (excess protein in the urine), reduced kidney function, and eventually kidney failure. Early Diabetic Kidney Disease symptoms are often subtle but may include swelling (edema), fatigue, and increased blood pressure. Diagnosis involves urine tests to detect albuminuria, blood tests to assess kidney function (eGFR), and imaging studies if necessary.
Management of Diabetic Kidney Disease focuses on controlling blood sugar and blood pressure to slow disease progression. First-line treatments include renin-angiotensin-aldosterone system (RAAS) inhibitors like ACE inhibitors or ARBs. Newer therapies, such as SGLT2 inhibitors and GLP-1 receptor agonists, have shown promise in protecting kidney function. Lifestyle modifications, including a low-protein diet and regular exercise, also play a crucial role. Early detection and intervention are essential in preventing ESRD and the need for dialysis or transplantation.
Get a Free Sample PDF Report to know more about Diabetic Kidney Disease Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/diabetic-kidney-disease-dkd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Emerging Diabetic Kidney Disease Drugs Under Different Phases of Clinical Development Include:
• ORBCEL-M: Orbsen Therapeutics
• DMX-200: Dimerix Bioscience
• INV-202: Inversago Pharma
• CSL346: CSL Behring
• Bardoxolone methyl: Kyowa kirin
Diabetic Kidney Disease Pipeline Therapeutics Assessment
• Diabetic Kidney Disease Assessment by Product Type
• Diabetic Kidney Disease By Stage and Product Type
• Diabetic Kidney Disease Assessment by Route of Administration
• Diabetic Kidney Disease By Stage and Route of Administration
• Diabetic Kidney Disease Assessment by Molecule Type
• Diabetic Kidney Disease by Stage and Molecule Type
DelveInsight's Diabetic Kidney Disease Pipeline Report covers around 5+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Further Diabetic Kidney Disease product details are provided in the report. Download the Diabetic Kidney Disease pipeline report to learn more about the emerging Diabetic Kidney Disease therapies at:
https://www.delveinsight.com/sample-request/diabetic-kidney-disease-dkd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Some of the key companies in the Diabetic Kidney Disease Therapeutics Market include:
Key companies developing therapies for Diabetic Kidney Disease are - Janssen Pharma, Astrazeneca, Aurobindo Pharma, Teva Pharma, Sanofi, Novartis, Sun Pharma, Bayer, Par Pharma, and others.
Diabetic Kidney Disease Pipeline Analysis:
The Diabetic Kidney Disease pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Diabetic Kidney Disease with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Diabetic Kidney Disease Treatment.
• Diabetic Kidney Disease key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Diabetic Kidney Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Diabetic Kidney Disease market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Diabetic Kidney Disease drugs and therapies-
https://www.delveinsight.com/sample-request/diabetic-kidney-disease-dkd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Diabetic Kidney Disease Pipeline Market Drivers
• Increasing prevalence of diabetes worldwide, rising geriatric population, increasing demand of novel therapies are some of the important factors that are fueling the Diabetic Kidney Disease Market.
Diabetic Kidney Disease Pipeline Market Barriers
• However, lack of skilled professionals to treat diabetic kidney disease in less developed countries, stringent regulatory guidelines and other factors are creating obstacles in the Diabetic Kidney Disease Market growth.
Scope of Diabetic Kidney Disease Pipeline Drug Insight
• Coverage: Global
• Key Diabetic Kidney Disease Companies: Orbsen Therapeutics, Dimerix Bioscience, Inversago Pharma, CSL Behring, Kyowa kirin, and others
• Key Diabetic Kidney Disease Therapies: ORBCEL-M, DMX-200, INV-202, CSL346, Bardoxolone methyl, and others
• Diabetic Kidney Disease Therapeutic Assessment: Diabetic Kidney Disease current marketed and Diabetic Kidney Disease emerging therapies
• Diabetic Kidney Disease Market Dynamics: Diabetic Kidney Disease market drivers and Diabetic Kidney Disease market barriers
Request for Sample PDF Report for Diabetic Kidney Disease Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/diabetic-kidney-disease-dkd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Table of Contents
1. Diabetic Kidney Disease Report Introduction
2. Diabetic Kidney Disease Executive Summary
3. Diabetic Kidney Disease Overview
4. Diabetic Kidney Disease- Analytical Perspective In-depth Commercial Assessment
5. Diabetic Kidney Disease Pipeline Therapeutics
6. Diabetic Kidney Disease Late Stage Products (Phase II/III)
7. Diabetic Kidney Disease Mid Stage Products (Phase II)
8. Diabetic Kidney Disease Early Stage Products (Phase I)
9. Diabetic Kidney Disease Preclinical Stage Products
10. Diabetic Kidney Disease Therapeutics Assessment
11. Diabetic Kidney Disease Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Diabetic Kidney Disease Key Companies
14. Diabetic Kidney Disease Key Products
15. Diabetic Kidney Disease Unmet Needs
16 . Diabetic Kidney Disease Market Drivers and Barriers
17. Diabetic Kidney Disease Future Perspectives and Conclusion
18. Diabetic Kidney Disease Analyst Views
19. Appendix
20. About DelveInsight
Trending Reports:
• Hearing Aid Devices Market: https://www.delveinsight.com/report-store/hearing-aid-devices-market
• Hpv-induced Cancers Market: https://www.delveinsight.com/report-store/human-papillomavirus-16-positive-hpv16-cancers-market
• Neurotrophic Keratitis Market: https://www.delveinsight.com/report-store/neurotrophic-keratitis-market
• 3d Cardiac Mapping System Market: https://www.delveinsight.com/report-store/3d-cardiac-mapping-system-market
• Acquired Immunodeficiency Syndrome Market: https://www.delveinsight.com/report-store/acquired-immunodeficiency-syndrome-aids-pipeline-insight
• Actinic Keratosis Market: https://www.delveinsight.com/report-store/actinic-keratosis-market
• Acute Pancreatitis Market: https://www.delveinsight.com/infographics/acute-pancreatitis-market
• Acute Pulmonary Embolism Market: https://www.delveinsight.com/report-store/acute-pulmonary-embolism-market
• Age-related Macular Degeneration Market: https://www.delveinsight.com/report-store/age-related-macular-degeneration-amd-market
• Alpha Antitrypsin Market: https://www.delveinsight.com/report-store/alpha-1-antitrypsin-deficiency-a1atd-market
• Arteriovenous Fistula Market: https://www.delveinsight.com/report-store/arteriovenous-fistula-market
• Cerebral Aneurysm Market: https://www.delveinsight.com/report-store/intracranial-aneurysms-market-insight
• Chronic Lymphocytic Leukemia Cll Market: https://www.delveinsight.com/report-store/chronic-lymphocytic-leukemia-cll-market
• Eczema Market: https://www.delveinsight.com/report-store/atopic-dermatitis-market
• Endoscopy Fluid Management Systems Market: https://www.delveinsight.com/blog/endoscopy-fluid-management-systems-market
• Gout Market: https://www.delveinsight.com/report-store/gout-market
• Graves' Disease Market: https://www.delveinsight.com/report-store/graves-disease-market
• Human Papilomavirus Market: https://www.delveinsight.com/report-store/human-papillomavirus-hpv-market
• Interbody Cages Market: https://www.delveinsight.com/report-store/interbody-cages-market
• Neuromodulation Devices Market: https://www.delveinsight.com/report-store/neuromodulation-devices-market
• Palmar Hyperhidrosis Market: https://www.delveinsight.com/report-store/palmar-hyperhidrosis-market
• Partial Seizure Market: https://www.delveinsight.com/report-store/partial-epilepsy-market
• Pediatric Obesity Market: https://www.delveinsight.com/report-store/pediatric-obesity-market
• Prader-willi Syndrome Market: https://www.delveinsight.com/report-store/prader-willi-syndrome-market
• Vascular Access Devices Market: https://www.delveinsight.com/report-store/vascular-access-device-market
• Vertigo Market: https://www.delveinsight.com/report-store/vertigo-market
• Acanthamoeba Keratitis Market: https://www.delveinsight.com/report-store/acanthamoeba-keratitis-market
• Acne Vulgaris Market: https://www.delveinsight.com/report-store/acne-vulgaris-av-market
Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/consulting/primary-research-services
Case study: https://www.delveinsight.com/case-study/cutaneous-squamous-cell-carcinoma-epidemiology-assessment
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Diabetic Kidney Disease Clinical Trials and Pipeline Analysis: EMA, PDMA, FDA Approvals, Medication, NDA, IND, Therapies, Treatment Market, Mechanism of Action, Route of Administration, and Companies by DelveInsight here
News-ID: 3865939 • Views: …
More Releases from DelveInsight Business Research
Global Tumor Ablation Market to reach USD 4,595.68 million by 2032 at a CAGR of …
According to DelveInsight's analysis, The global Tumor Ablations (EHR) market is experiencing significant growth, driven by the increasing prevalence of chronic diseases that require continuous monitoring, data management, and coordinated long-term care. This demand has fueled the need for integrated healthcare systems capable of connecting patient information across multiple departments and care settings. To support this trend, governments worldwide are introducing initiatives, funding, mandates, and regulatory frameworks to promote EHR…
Global Spinal Implants Market to reach USD 21,899.24 million by 2032 at a CAGR o …
According to DelveInsight's analysis, The increasing prevalence of spinal disorders, especially among the aging population, has substantially driven the demand for corrective surgical procedures. At the same time, the rise in sports-related and trauma-induced spinal injuries is boosting the need for advanced implantable solutions. Additionally, there is a growing preference for non-fusion and motion-preserving devices that maintain spinal mobility and improve patient outcomes, particularly among younger and more active individuals.…
Global Vascular Stents Market to reach USD 18,277.68 million by 2032 at a CAGR o …
According to DelveInsight's analysis, The increasing global incidence of cancer is boosting the demand for effective treatment options such as tumor ablation. Minimally invasive procedures are becoming more popular due to their shorter recovery periods, reduced risks, and cost-effectiveness compared to conventional surgery. At the same time, technological advancements in tumor ablation devices-such as improvements in radiofrequency, microwave, and cryoablation technologies-have enhanced precision, safety, and effectiveness, making these procedures increasingly…
Global Vascular Grafts Market to reach USD 3,153.39 million by 2032 at a CAGR of …
According to DelveInsight's analysis, The increasing prevalence of cardiovascular disorders, along with risk factors like hypertension, diabetes, and obesity, is fueling the demand for surgical interventions, thereby supporting the growth of the vascular graft market. Moreover, greater awareness and the expansion of cardiovascular screening programs are enabling earlier diagnosis and timely treatment, further driving the need for vascular grafts.
DelveInsight's "Vascular Grafts Market Insights, Competitive Landscape and Market Forecast-2032" report provides…
More Releases for Disease
Protheragen Announces Disease Model Development Services to Enhance Rare Disease …
Protheragen announced the release of its disease model development services provided to enhance rare disease research. With an increasing focus on rare diseases and the need for tailored research models, Protheragen is dedicated to providing cutting-edge solutions to support this important area of medical research.
Rare diseases, which affect a small percentage of the population, pose unique challenges for researchers due to their limited understanding and lack of available treatment options.…
Biopharmaceutical Fermentation Market 2022 | Growing Morbidity of Genetic Diseas …
According to Precision Business Insights (PBI), the latest report, the biopharmaceutical fermentation market is expected to be valued at USD 10,302.1 million in 2022, growing at a 4.7% CAGR from 2022 to 2028. The growing prevalence of chronic illness, cancer, cardiac diseases, infectious diseases, antibiotic resistance, autoimmune diseases, etc., globally causes the leaning toward biopharmaceutical products, which show promising results in the research studies. Moreover, new findings by the…
Global Inflammatory Bowel Disease (IBD) Market Key Players Analysis, Disease Ind …
Global Inflammatory Bowel Disease (IBD) Market, valued at USD 210.5 Billion in the year 2020 has been driven by factors such as the increasing prevalence of Ulcerative Colitis and Crohn’s Disease, advances in medical technology, government support for inflammatory bowel disease treatment research, and the ubiquity of anxiety and depression. Moreover, factors such as the irregular food habits, unhealthy lifestyle of people, increased level of pollution and increase in alcohol…
Moyamoya Disease Market - A Scientometric Assessment of Disease During 2018-23
Market Highlight:
Moyamoya disease (MMD) is a chronic, cerebrovascular disease characterized by progressive stenosis in the internal carotid artery and an abnormal vascular network at the base of the brain. The stroke is one of the significant symptoms of moyamoya disease, which further leads to paralysis of the face, arms, and legs, loss of speech, and temporary loss of neurologic function of body parts, visual disturbances, headaches, developmental delay, and…
Refsum Disease Industry An Overview of A New Disease - 2018
"Refsum Disease" is a genetic disorder which is inherited as an autosomal recessive trait. The condition is characterized by progressive loss of vision (retinitis pigmentosa), failure of muscle coordination (ataxia), degenerative nerve disease (peripheral neuropathy), and dry, rough, scaly skin (ichthyosis). The accumulation of fatty acid (phytanic acid) in blood plasma and tissues is the main cause of refsum disease. This occurs due to malfunction of the enzyme producing gene…
Chagas Disease (Infectious Disease) Pipeline Forecast Report, H1, 2017 [MRH]
Market Research Hub's Pharmaceutical and Healthcare latest pipeline guide Chagas Disease - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Chagas Disease Market (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and…
